


The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


1. (Currently Amended) ~~The use of a compound of a~~ A compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, ~~in the preparation of a composition for inhibition of HSP90 activity for use in human or veterinary medicine:~~



wherein

ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms;

R₁ is attached to a first ring atom of ring A and is a group of formula (IA):



wherein in any compatible combination

Ar¹ is an optionally substituted aryl or heteroaryl radical,

Alk¹ and Alk² are optionally substituted divalent C₁-C₆ alkylene or C₂-C₆ alkenylene radicals,

p, r and s are independently 0 or 1,

Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO₂-, -C(=O)O-, -C(=O)NR^A-, -C(=S)NR^A-, -SO₂NR^A-, -NR^AC(=O)-, -NR^ASO₂- or -NR^A- wherein R^A is hydrogen or C₁-C₆ alkyl, and

Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical;

R₂ is attached to a second ring atom of ring A, which is adjacent the first ring atom to which

R₁ is attached, or is absent if that ring atom is a nitrogen atom which is double bonded to a ~~neighbouring~~neighboring ring atom, and if not absent R₁ is hydrogen or


(i) a group of formula (IA) as defined in relation to R₁; .

(ii) a carboxamide radical; or


(iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula - (Alk¹)_p-(Z)_r(Alk²)_s-Q wherein Q, Alk¹, Alk², Z, p, r and s are as defined above in relation to group (IA); and

R₃ is attached to a third ring atom of ring A, which is adjacent the second ring atom to which R₂ is attached, or is absent if that ring atom is a nitrogen atom which is double bonded to a ~~neighbouring~~neighboring ring atom, and if not absent R₂ is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C₁-C₆ alkyl, ~~C₄-C₆~~C₂-C₆ alkenyl, or ~~C₄-C₆~~C₂-C₆ alkynyl; or a carboxyl, carboxamide or carboxyl ester group,


PROVIDED THAT (a) at least one of R₂ and R₃ is present and is other than hydrogen and (b) the compound of formula (I) is not one of formula (IA) (IB), (IC) or (ID)




(IA)



(IB)




(IC)




(ID)

wherein R₁, R₂ and R₃ are as defined above, and R is ~~is~~ hydrogen or optionally substituted C₁-C₆ alkyl.

2. (Currently Amended) The ~~use compound~~ as claimed in claim 1 wherein the group the ring A is aromatic.
3. (Currently Amended) The ~~use compound~~ as claimed in claim 1 ~~or claim 2~~ wherein both R₁ and R₂ are attached to ring carbon atoms.
4. (Currently Amended) The ~~use compound~~ as claimed in claim 1 ~~or claim 2~~ wherein one of R₁ and R₂ is attached to a ring carbon atom and the other to a ring nitrogen atom.
5. (Currently Amended) The ~~use compound~~ as claimed in claim 1 wherein the ring A is a 1, 2, 4-tetrazolyl ring or a 1, 2, 3-triazole ring.
6. (Currently Amended) The ~~use compound~~ as claimed in claim 1 wherein the compound of formula (I) has formula (IE) or (IF)




(IE)



(IF)

wherein ~~R1, R2, and R3~~ R₁, R₂, and R₃ are as defined in claim 1.

7. (Currently Amended) The ~~use compound~~ as claimed in ~~any of the preceding claims~~ claim 1 wherein in the compound of formula (I) R₁ has formula (II):




wherein Alk^1 , Alk^2 , p , r , s , Z and Q are as defined above in relation to R_1 , and R represents one or more optional substituents.

8. (Currently Amended) The ~~use compound~~ as claimed in ~~any of the preceding claims claim 1~~ wherein in the group R_1 of the compound of formula (I) each of p , r and s is 0, and Q is hydrogen.

9. (Currently Amended) The ~~use compound~~ as claimed in claim 8 wherein R_1 is 2-hydroxyphenyl optionally further substituted by one or more of hydroxy, methyl, ethyl, methoxy, ethoxy, chloro, or bromo.

10. (Currently Amended) The ~~use compound~~ as claimed in ~~any of claims 1 to 8 claim 1~~ wherein in the compound of formula (I) R_1 has formula (IIA):



wherein R represents bromo, chloro, phenyl, C_1 - C_6 alkyl or phenyl(C_1 - C_6 alkyl)-.

11. (Currently Amended) The ~~use compound~~ as claimed in ~~any of claims 1 to 7 claim 1~~ wherein in the group R_1 of the compound of formula (I) one or more of p , r and s is 1.

12. (Currently Amended) The ~~use~~compound as claimed in claim 11 wherein p and/or s is/are 1 and r is 0.

13. (Currently Amended) The ~~use~~compound as claimed in claim 11 wherein each of p, r, and s is 1.

14. (Currently Amended) The ~~use~~compound as claimed in claim 11 wherein p and s are 0 and r is 1.

15. (Currently Amended) The ~~use~~compound as claimed in ~~any of the preceding claims~~claim 1 wherein R₂ is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl, optionally substituted by one or more of methoxy, ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, or trifluoromethyl.

16. (Currently Amended) The ~~use~~compound as claimed in ~~any of claims 1 to 14~~claim 1 wherein R₂ is optionally substituted phenyl.

17. (Currently Amended) The ~~use~~compound as claimed in ~~any of claims 1 to 14~~claim 1 wherein R₂ is a carboxamide radical of formula -CONR^B(Alk)_nR^A wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,
n is 0 or 1,

R^B is hydrogen or a C₁-C₆ alkyl or C₂-C₆ alkenyl group,

R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

or R^A and R^B taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms

selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

18. (Currently Amended) The ~~use compound~~ as claimed claim 17 wherein

Alk is an optionally substituted $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $\text{CH}_2\text{CH}=\text{CH}-$, or $-\text{CH}_2\text{CCCH}_2-$ radical.

n is 0 or 1 ,

R^{B} is hydrogen, methyl, ethyl, n- or iso-propyl, or allyl,

R^{A} is hydroxy, hydroxy and/or chloro-substituted phenyl, 3,4 methylenedioxyphenyl, pyridyl, furyl, thienyl, N-piperazinyl, or Nmorpholinyl,

or R^{A} and R^{B} taken together with the nitrogen to which they are attached form a morpholino, piperidiny, piperazinyl or N-phenylpiperazinyl ring.

19. (Currently Amended) The ~~use compound~~ as claimed in claim 17 wherein n is 0, R^{B} is hydrogen and R^{A} is hydroxy or an optionally substituted carbocyclic or heterocyclic ring.

20. (Currently Amended) The ~~use compound~~ as claimed in ~~any of the preceding claims~~ claim 1 wherein R_3 is hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, or hydroxyethyl.

21. (Currently Amended) The ~~use compound~~ as claimed in ~~any of claims 1 to 19~~ claim 1 wherein R_3 is a carboxamide group $-\text{CONR}^{\text{B}}(\text{Alk})_n\text{R}^{\text{A}}$ ~~as defined in any of claims 16 to 18 in relation to R_2~~ wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,
n is 0 or 1,

R^B is hydrogen or a C₁-C₆ alkyl or C₂-C₆ alkenyl group.

R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring.

or R^A and R^B taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

22. (Currently Amended) A method of treatment of diseases or conditions mediated by excessive or inappropriate HSP90 activity in mammals which method comprises administering to the mammal an amount of a compound of formula (I) as defined in ~~any of claims 1 to 21~~claim 1, or a salt, hydrate or solvate thereof, effective to inhibit said HSP90 activity.

23. (Currently Amended) ~~The use as claimed in any of claims 1 to 21 or a method as claimed~~ claim 21 for immunosuppression or the treatment of cancer; viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie/CJD, Huntingdon's and Alzheimer's disease.

24. (Canceled)

25. (Currently Amended) A pharmaceutical or veterinary composition comprising a compound as defined in ~~any of claims 1 to 21~~claim 1, or a salt hydrate or solvate thereof, together with a pharmaceutically or veterinarily acceptable carrier.